Premium
Estimation of the number of blood donors during the COVID ‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
Author(s) -
Yuan Zhaohu,
Chen Dandan,
Chen Xiaojie,
Wei Yaming
Publication year - 2020
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.15858
Subject(s) - incubation period , covid-19 , blood transfusion , medicine , transmission (telecommunications) , incubation , virology , blood collection , immunology , andrology , biology , emergency medicine , disease , computer science , infectious disease (medical specialty) , telecommunications , outbreak , biochemistry
BACKGROUND The aim of this study was to estimate the number of blood donors during the COVID‐19 incubation period across China. STUDY DESIGN AND METHODS In this study, we developed a predictive model to estimate the number of blood donors during the COVID‐19 incubation period among 34 provincial regions in China. Our main assumption was that blood donors of all ages in different regions have a stable blood donation intention and the same infection risk. RESULTS First, we estimated the number of blood donors during the COVID‐19 incubation period in Wuhan city, Hubei Province, and China, from December 31, 2019 to March 17, 2020. Second, we compared the number of blood donors during the COVID‐19 incubation period in all provinces across China. In addition, we found that if all RBCs, plasma, and cryoprecipitation were stored in isolation until the 14th day, the potential risk of SARS‐CoV‐2 transmission through blood transfusion was reduced by at least 65.77% after the blood donor safely passed the COVID‐19 incubation period. Moreover, if the detection of SARS‐CoV‐2 RNA was carried out on all platelets, the potential risk would be reduced by 77.48%. CONCLUSIONS Although the risk is low, with the rapid spread of the COVID‐19 and the appearance of alarmingly high infectivity and a high fatality rate, appropriate measures should be taken by health departments to ensure the safety of clinical blood.